The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Adaptimmune; Bayer; Caris Life Sciences; CytRx Corporation; Daiichi Sankyo; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Novartis; Pfizer; Plexxikon; Polaris; Threshold Pharmaceuticals
Speakers' Bureau - Adaptimmune; Caris Life Sciences; GlaxoSmithKline; Janssen; Lilly; Novartis
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the use of ME1 as Biomarker. Patent on ALEXT#102
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline
Other Relationship - OncLive
A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results.
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Minal A. Barve
No Relationships to Disclose
 
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Andrew Jacob Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX
Honoraria - Vascular Biogenics
Consulting or Advisory Role - NanoTX; Vascular Biogenics
Research Funding - miRNA Therapeutics (Inst); Threshold Pharmaceuticals; Vascular Biogenics
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics
 
Frances Valdes
Honoraria - Adverum (I); Allegro Ophthalmics (I); Allergan (I); BVI (I); EyePoint Pharmaceuticals (I); Genentech (I); Janssen Biotech (I); Novartis (I); Santen (I); Valeant Pharmaceuticals International (I)
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Valeria González
Travel, Accommodations, Expenses - Roche
 
Banmeet S. Anand
Employment - Molecular Templates
Stock and Other Ownership Interests - Molecular Templates
Travel, Accommodations, Expenses - Molecular Templates
 
Christine Burnett
Employment - Molecular Templates
Stock and Other Ownership Interests - Molecular Templates
 
Joshua Pelham
Employment - Molecular Templates
Stock and Other Ownership Interests - Molecular Templates
Consulting or Advisory Role - Molecular Templates
Travel, Accommodations, Expenses - Molecular Templates
 
Roger J. Waltzman
Employment - Molecular Templates; Rgenix
Leadership - Molecular Templates; Rgenix
Stock and Other Ownership Interests - Molecular Templates; Rgenix
 
Thomas Strack
Employment - Molecular Templates
Stock and Other Ownership Interests - Molecular Templates
Travel, Accommodations, Expenses - Molecular Templates
 
Brian A. Van Tine
No Relationships to Disclose